Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alexza Pharma refiles schizophrenia drug NDA with FDA
AZ-004 is indicated as a treatment of agitation in patients with schizophrenia or bipolar disorder. In the original CRL, the Center for Drug Evaluation and Research of FDA
AZ-004 is indicated as a treatment of agitation in patients with schizophrenia or bipolar disorder. In the original CRL, the Center for Drug Evaluation and Research of FDA
The new name aligns with the company’s core technology – transdermal absorption of pharmaceutical agents. Promescent, which employs a proprietary, eutectic mixture of lidocaine and other compounds, delivers
Sohm has rolled out the products through its Indian manufacturing and marketing facility under Diorac brand name. Sohm CEO Shailesh Shah said Diorac is a combination of prebiotic
The drug, which is a solution formulation, has been approved in 200mg, 1gm and 2gm with a concentration of 38 mg/ml strength. The company expects to roll out
As per the agreement, the holders of Emdeon common stock are expected to get around $19 per share in cash. Following the merger, Emdeon will become a privately
Firefly will utilize the grant to braden its production capacity and also to assess its microRNA assay. MicroRNAs are a class of biomarkers which are used as indicators
Dyadic’s net loss was $736,204, or $0.02 loss per diluted share, compared to $1.41m, or $0.05 per diluted share, for the same period in 2010. The company’s loss
The trial aims to compare the effectiveness and safety of conventional therapy treatment plus ecallantide to conventional therapy treatment plus placebo in 176 patients recruited at 40 US
Botanical Science Technologies will become the subsidiary of IMD Companies. The marketing plan includes on-line sales services, direct distribution through participating weight-loss centers and licensed consignment agreements with
Lebrikizumab, developed by Genentech Research and Early Development, is a humanized monoclonal antibody designed to block the IL-13 cytokine and reduce inflammation in the lung. The study, which